Cointime

Novosteo

company

About

Novosteo, test the efficacy of a new drug to help reduce complications from a broken bone due to a fall.

  • 1 - 10

Highlights

Total Funding Amount
$1.70M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Grant
Last Funding Money Raised
$1.70M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active

Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone metastasis and infection. Scientific co-founders Stewart Low and Philip Low of Purdue University have created a proprietary chemistry approach to bone targeting and have discovered novel biologics that accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$1.70M
Novosteo has raised a total of $1.70M in funding over 2 rounds. Their latest funding was raised on Sep 27, 2018 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 27, 2018 Grant $1.70M 1 National Institutes of Health — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Novosteo is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
Cointime
İçerikler
Şirket.